Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior VEGFR-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study

CONCLUSIONS: Results indicate that cabozantinib benefits patients with radioiodine-refractory DTC, regardless of prior lenvatinib or sorafenib treatments or histology.PMID:38062732 | DOI:10.1089/thy.2023.0463

Source: Thyroid : official journal of the American Thyroid Association - December 8, 2023 Category: Endocrinology Authors: Jaume Capdevila Jolanta Krajewska Jorge Hernando Bruce Robinson Steven I Sherman Barbara Jarzab Chia-Chi Lin Fernanda Vaisman Ana Oliveira Hoff Erika Hitre Daniel Bowles Denise Williamson Roman Levytskyy Jennifer W Oliver Bhumsuk Keam Marcia Brose Source Type: research